EMA to go extra mile to facilitate joint safety study for valproate
This article was originally published in SRA
Executive Summary
In the course of its mandate to help companies carry out joint post-authorization safety studies under the EU pharmacovigilance legislation, the European Medicines Agency is planning to organize a teleconference/webinar for a new study concerning the anti-epileptic drug valproate so that interested companies may be introduced to each other and have the opportunity to interact and raise questions.
You may also be interested in...
EMA Urged To Do Better On Valproate Risk Reduction In Pregnant Women
There were passionate testimonies from patients affected by Sanofi’s anti-epileptic drug valproate at the European Medicines Agency's first public hearing on medicines safety. There was almost full agreement among those who testified that existing risk reduction measures are not working.
EMA Poses Three Questions For the Public Ahead Of Valproate Hearing
The European Medicines Agency will be choosing speakers for its public hearing on valproate in September based on how they propose to address three questions. Pharmaceutical companies can apply too.
Valproate In The Spotlight As EMA Releases Date For First Ever Public Hearing
The European Medicines Agency has released the date for its public hearing on valproate in which EU citizens will for the first time be given a voice in evaluating the safety of medicines on the market.